跳至主要内容
临床试验/CTRI/2022/03/041120
CTRI/2022/03/041120尚未招募4 期

Evaluation of the benefit of using a composite formulation containing silver nanoparticle in patients with infected wounds compared to standard wound management: A prospective randomised open label parallel clinical trial

Kalinga Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Male or female patients aged more than 18 years of age
  • 2. Patients admitted with infected wound with swab/pus/tissue culture positive for a bacteria
  • 3. Wound of any type and any area (body part) including either post-surgery, trauma, burn or chronic underlying illness like diabetes
  • 4.Willingness to comply with study instructions for its duration as indicated by written informed consent from the patient

排除标准

  • 1. Pregnant or breastfeeding women,
  • 2. The wound with underlying cancer
  • 3. Patients with underlying immunocompromised status (infected with HIV, any immunodeficiency)
  • 4. Patient is sick enough requiring life support or vasopressors.
  • 5.Participation in any clinical study, which may interfere with the current study

研究者

相似试验